XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Debt - Liability for Sale of Future Royalties Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Oct. 18, 2023
USD ($)
Option
Jul. 17, 2020
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2025
USD ($)
tranche
Dec. 31, 2024
USD ($)
Assigned royalty payments          
Assigned royalty payment, retained percentage   57.067%      
Remaining potential milestones that can be achieved         $ 150.0
Effective interest rate of the liability component       9.30%  
Aggregate Royalty Purchase Agreements | Royalty Pharma          
Assigned royalty payments          
Aggregate percentage of royalty rights sold 80.9777%        
Original Royalty Purchase Agreement          
Assigned royalty payments          
Assigned royalty payment, percentage   42.933%      
Cash consideration received from A&R Royalty Purchase Agreement   $ 650.0      
Royalty purchase agreement termination period once there are no further royalty payment obligations   60 days      
Assigned Royalty Cap per terms of the royalty purchase agreement $ 1,300.0 $ 1,300.0      
A&R Royalty Purchase Agreement          
Assigned royalty payments          
Cash consideration received from A&R Royalty Purchase Agreement $ 1,000.0   $ 241.8    
Assigned royalty payment, retained percentage       9.51%  
Royalty purchase agreement termination period once there are no further royalty payment obligations 60 days     60 days  
Effective interest rate of the liability component 10.80%   9.90%    
Retained Royalty Rights percentage sold 38.0447%        
Percentage of total royalty payable after threshold royalties received 66.6667%        
Additional cash consideration $ 500.0        
Aggregate percentage of royalty rights sold       90.49%  
Number of put options held by the company | Option 5        
Maximum number of put options which can be exercised before Royalty Pharma can exercise a call option | Option 2        
Maximum percentage of remaining retained royalty rights that are available upon exercise of call option 50.00%        
Percentage of maximum royalty payable until assigned royalty rights       83.33%  
Liability recognized for sale of future royalties.     $ 241.8    
Fair value of liability for sale of future royalties. $ 1,809.9        
Loss on extinguishment of debt $ 44.9        
Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met       16.67%  
A&R Royalty Purchase Agreement | Maximum          
Assigned royalty payments          
Number of tranches to sell retained royalty | tranche       3  
A&R Royalty Purchase Agreement | Royalty Pharma          
Assigned royalty payments          
Percentage of maximum royalty payable until assigned royalty rights 90.4888%        
Percentage of maximum royalty payable thereafter assigned royalty rights 83.3333%        
A&R Royalty Purchase Agreement | Royalty Pharma          
Assigned royalty payments          
Assigned Royalty Cap per terms of the royalty purchase agreement       $ 1,300.0  
Aggregate upfront cash consideration received for sale of future royalties       $ 1,900.0  
A&R Royalty Purchase Agreement Tranche One          
Assigned royalty payments          
Aggregate percentage of royalty rights sold       3.81%  
Contract price for sale of specified percentage of future royalties       $ 100.0  
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met       6.67%  
A&R Royalty Purchase Agreement Tranche Two          
Assigned royalty payments          
Aggregate percentage of royalty rights sold       3.81%  
Contract price for sale of specified percentage of future royalties       $ 100.0  
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met       6.67%  
A&R Royalty Purchase Agreement Tranche Three          
Assigned royalty payments          
Aggregate percentage of royalty rights sold       1.90%  
Contract price for sale of specified percentage of future royalties       $ 50.0  
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met       3.33%